Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
The galaxy of pharma leaders from top US companies grudgingly admit- ted despite many difficult areas, India remains a huge emerging market for pharmaceutical products. They urged the nearly 200 participants to build a capability-driven strategy to emerge winners in this promising marketplace.
The USA-India Chamber of Commerce (USAIC) will organize its 9th annual Bio- Pharma & Healthcare Sum- mit on June 11 at the Marriott Cam- bridge, Massachusetts, USA.
India’s health and innovative and biopharma sector deserves better attention from the government to help realise its full potential and provide much cheaper health care and medicine to millions of patients, leading Biopharma industry experts and academicians have said.
BOSTON:India’s health and innovative and biopharma sector deserves better attention from the government to help realise its full potential and provide much cheaper health care and medicine to millions of patients, leading Biopharma industry experts and academicians have said.
WASHINGTON, D.C. — India’s healthcare innovation and biopharma sector deserves better attention from the government to help realize its full potential and provide much cheaper health care and medicine to millions of patients, leading biopharma industry experts and academicians have said.
India needs to build an effective innovation ecosystem to realise its full potential in the field of research and development particularly in the biopharma and health sector, a report said today.
With some in- vestments in creating in- novative Bio- Pharma prod- ucts, India could address the huge unmet needs of four billion people in the health- care sector worldwide instead of just her own 1.2 billion people, says a special report by global management consultancy, McKinsey.
The USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce, will organize its annual US-India Bio- Pharma and Healthcare Summit on June 27 at the Marriott Cam- bridge, Massachusetts, USA.
A month after the Narendra Modi government took charge in New Delhi, health- care experts from In- dia and the US gath- ered in Cambridge, Massachusetts, for the annual US-India BioPharma and Healthcare Summit on June 28, 2014. The mood was somber just the way it had been at this much-await- ed event in the last two years. For the promise of great collaborations between the two countries in the healthcare arena had yet to make sig- nificant progress in the last decade
Global pharma companies argue that they share goal of ‘patient first’ with that of Indian govt.
BOSTON: Top executives of American pharma companies favour “dialogue” with India and “not confrontation” to address their concerns on key issues like the protection of intellectual property (IP) and clinical trials.
A Ministry of Health official addressed concerns that India’s clinical trail policies are an impediment to local innovation and asserted that the country.
The US India Biopharma and Healthcare Summit 2013, organized by the USA-India Chamber of Commerce and held here June 21, attracted more than 300 people to the annual conference.
India’s pharmaceutical market will more than double from the current year’s $18 billion to over $45 billion by the ear 2020, predicts a major study by global consultants McKinsey & Company.
India’s pharmaceutical market will more than double from the current year’s $18 billion to over $45 billion by the ear 2020, predicts a major study by global consultants McKinsey & Company.
McKinsey singles out clinical trial policies as the top obstacle to Indian innovation, but also takes a closer look at IP issues that could be holding the country back
Despite recent news flow focused on a challending patent environment, India’s pharma market is expected to grow 13% annually to reach $45 billion by 2020.
WASHINGTON: Amid serious concerns among US businesses and lawmakers over intellectual property protection in India, a new report says clinical trials, infrastructure and policy are the biggest obstacles in driving research and development innovation at scale in India’s healthcare sector.
Pharma Asia News» View Pdf
Mounting expectations from India as an emerging nationpharma powerhouse were tempered with concerns on he policy front at this year’s US-India BioPharma& Healthcare Summit in Cambridge, Massachusetts.
BOSTON: Noting that India has the ability to be a “global hub” in the bio-pharma and healthcare sector, industry leaders have said that steps need to be taken to realize the huge untapped potential in this field.
Noting that India has the ability to be a “global hub” in the bio-pharma and healthcare sector, industry leaders here have said New Delhi needs to take steps to realise the huge untapped potential in this field.
The U.S.-India Bio- Pharma and Healthcare Summit 2012, organized by the USA-India Chamber of Commerce at the Hyatt Regency here May 11, served as a powerful platform for American and Indian companies to come together and build global partnerships to deliver innovation in healthcare and the biopharma industry.
During the annual USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.
The USA-India Chamber of Commerce, a bilateral chamber of commerce, will hold its annual U.S.-India Bio- Pharma & Healthcare Summit May 11 at the Hyatt Cambridge here.
More than 200 healthcare experts from India and the US gathered again for an annual session in early May 2012 to discuss how India’s biotech industry can play a leading role in innovating to make healthcare affordable globally.
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Washington, May 9 (PTI) Emerging markets will drive 70 per cent of growth in the pharma industry and India will require supportive policies to leverage the BioPharma opportunity to become an innovation hub for the sector, says a BCG report.
Washington: Emerging markets will drive 70 per cent of growth in the pharma industry and India will require supportive policies to leverage the BioPharma opportunity to become an innovation hub for the sector, says a BCG report.
WASHINGTON: Emerging markets will drive 70 per cent of growth in the pharma industry and India will require supportive policies to leverage the BioPharma opportunity to become an innovation hub for the sector, says a BCG report.
BOSTON: Aiming to acquire technologies that have been developed and which can be commercialised to put for public good, the Indian Government is planning to establish an ambitious technology acquisition fund by next year.
Noting that India has the ability to be a ‘global hub’ in the bio-pharma and healthcare sector, industry leaders here have said that New Delhi needs to take steps to realise huge untapped potential in this field. Indian government officials, attending a day-long brain-storming session in Boston, said that they are taking concrete steps in this regard.
US—India BioPharma and Healthcare Summit 2012 is all set to act as a platform for global R&D leaders to converge and share their views.
US—India BioPharma and Healthcare Summit 2012 is all set to act as a platform for global R&D leaders to converge and share their views.
Our News Bureau Mumbai USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce is rganising the annual US-India BioPharma and Healthcare Summit on May 11, 2012 at President’s Ballroom, Hyatt egency Cambridge, Massachusetts, US.
CXOs from the global biopharma shared the dais with their Indian counterparts in a frank sharing of concerns and suggested solutions focussed on how India can align more closely with their agendas for a win-win situation. Viveka Roychowdhury reports
BOSTON: India’s bio-pharma sector may see a surge in R&D spendingto about USD 25 billion in the next 15 years, according to a Boston Consulting Group report that saidfavourable policies need to be implemented to attract investment and enhance innovation in the field. The total amount that is currently being spent on innovative discovery programmes and development in thebio-pharma sector in India is about USD 2 billion. This amount can grow to USD 25 billion by 2025 if concerted efforts are made by various stakeholders likethe government, academia and industry on developing R&D and innovation in the bio-pharma field.
CAMBRIDGE, Mass. – The ever-growing engagement of the Indian pharmaceutical industry with its global counterparts – in the areas of R&D partnerships, manufacturing alliances to M&As – could be gauged from the coming together of senior level industry executives from both sides at the annual biopharma and healthcare summit sponsored by the USA-India Chamber of Commerce (USAIC) in Cambridge, Massachusetts June 23.
BOSTON–(BUSINESS WIRE)–Jun 23, 2011 – More than 70 percent of the 40 globalBioPharma executives in a recent survey are satisfied with their R&D alliances in India, andthree out of four expect to increase their R&D activities in India. Despite such positiveappraisals, India continues to play a relatively small role in BioPharma innovation, accordingto a new report by The Boston Consulting Group (BCG).
BOSTON, JUNE 24: India’s bio-pharma sector may see a surge in R&Dspending to about $25 billion in the next 15 years, according to a BostonConsulting Group report that said favourable policies need to be implementedto attract investment and enhance innovation in the field.
The total amount that is currently being spent on innovative discoveryprogrammes and development in the bio-pharma sector in India is about $2billion.
BOSTON, JUNE 22: The USA-India Chamber of Commerce will host theannual ‘US-India BioPharma and Healthcare Summit’ here on June 23, whichwill focus on India’s potential to become a hub of innovation in the field of bio-pharma. The summit will focus on issues such as overcoming barriers to buildingcollaborative partnerships between Indian and global companies, drugdiscovery and development and restructuring R&D to maximise productivityand clinical research.
Boston India’s bio-pharma sector may see asurge in R&D spending to about $ 25 billionin the next 15 years, according to a BostonConsulting Group report that said favourablepolicies need to be implemented to attractinvestment and enhance innovation in thefield.
India’s bio-pharma sector may see a surge in R&D spending to about USD 25 billion in the next 15years, according to a Boston Consulting Groupreport that said favourable policies need to beimplemented to attract investment and enhanceinnovation in the field.
Partnerships between US and Asian companies have become a prominent feature ofpharmaceutical development and manufacturing. To foster relationships between US andIndian biopharmaceutical companies, the US–India BioPharma and Healthcare Summitwas held in Cambridge, MA on June 23, 2011. The summit is an annual event, bringingtogether representatives from large US/European pharmaceutical companies, smaller UScompanies, academia, and patient interest groups with representatives of the Indiangovernment and industry to discuss issues surrounding US–Indian partnering inbiopharmaceutical development.
More than 70 percent of the 40 global BioPharma executives in a recent survey are satisfied withtheir R&D alliances in India, and three out of four expect to increase their R&D activities in India.Despite such positive appraisals, India continues to play a relatively small role in BioPharmainnovation, according to a new report by The Boston Consulting Group (BCG).
The report, which was commissioned by the USA-India Chamber of Commerce (USAIC) andbased on in-depth research, interviews, and a quantitative survey with over 40 R&D decisionmakers, will be released June 23 during the annual USA-India BioPharma & Healthcare Summit inCambridge, Massachusetts.
Research-related investments funnelled into India by U.S.-based pharmaceutical companies swelled by 10 times between 2002 and 2009 to reach $121 million, a number that will continue to grow in the years to come, according to an upcoming study by the Boston Consulting Group. The report, which was commissioned by the USA-India Chamber of Commerce (USAIC), will be released June 23 during the annual USA-India BioPharma & Healthcare Summit in Boston.
The Summit will focus on overcoming the barriers to building collaborative partnerships between the Indian and global companies. Panel discussions and keynotes will cover drug discovery and development, restructuring R&D to maximise productivity and innovation, pre-competitive alliances, industry-academic partnerships, clinical research, funding innovation and cross border M&A trends.
The USA-India Chamber of Commerce (USAIC) is set to organize its annual US-India BioPharma & Healthcare Summit on June 23, 2011, at Hyatt Cambridge, Massachusetts, USA. The event will highlight India’s potential to become a hub of innovation in the biopharma sector.
The annual Budget presented by the Finance Minister, Mr Pranab Mukherjee, has been hailed by a US-India business chamber as pragmatic and growth-oriented.
“Increase in healthcare and infrastructure expenditure is a positive step. We hope a serious attempt is made in the coming years to promote research and development in BioPharma,” said Karun Rishi, the president of the USA-India Chamber of Commerce (USAIC).
Deccan Herald – View PDF
Yahoo News – View PDF
Business Today – View PDF
MSN News – View PDF
The BioSpectrum awardees were unanimously chosen by the 8th BioSpectrum Awards Jury headed by Mr Hari S Bhartia, co-chairman and MD, Jubilant Life Sciences. The award ceremony took place at Hotel Leela Palace in Bangalore. There were two categories of awards. Jury Awards – selected by the jury and Company Awards given on the basis of the BioSpectrum-ABLE annual industry survey the results of which are published in the June & July (2010) issues of BioSpectrum.
Conference in Cambridge, Mass. — Organized by the USA-India Chamber of Commerce and Supported by The Boston Consulting Group — Will Focus on Overcoming Barriers to Increased Collaboration Between Global and Local Companies
The Summit focussed on the need for greater and more transparent collaborations, and the perils of spending more money protecting early-stage intellectual property (IP) than on early-stage research.
CAMBRIDGE, Mass. – Greater R&D collaboration was the theme of the day at the star-studded U.S.-India
Chamber of Commerce biopharma and healthcare summit…..
CAMBRIDGE, Mass. – Life science companies looking to provide healthcare solutions to the poorer, “bottom of the pyramid” – a population reaching more than 600 million people in India alone – should focus on business model innovation as much as on innovative products,….
The USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce aimed at promoting and facilitating tradeand investment between the US and India is organising its annual US-India BioPharma & Healthcare Summit on May 6th, at Hyatt Regency Cambridge, Massachusetts, USA….
Washington Bullish on the Indo-US BioPharma trends, the US-India Chamber of Commerce (USAIC) in its latest positionpaper has said Indian health care sector ispoised to take off along with the economy….
Bullish on the Indo-US Bio Pharma trends, the US-India Chamber of Commerce (USAIC) in its latest position paper has said Indian healthcare sector is poised to take off along with the economy…
Reflecting the emergence of India as a top global destination for research and development in the bio-pharma sector,leading industry leaders, investors, academicians and policy makers would attend a day-long US-India Bio-Pharma and Healthcare Summit in Boston in May…
WASHINGTON: Reflecting the emergence of India as a top global destination for research anddevelopment in the bio-pharma sector, leading industry leaders, investors, academicians andpolicy makers would attend a day-long US-India Bio-Pharma and Healthcare Summit in Boston in May….
GhoshBoston, MA: US-India BioPharma and Healthcare Summit 2010 organized by the USA-India Chamber of Commerce here on July 26, attracted over 350 senior bio-pharma executives, investors and academic leaders…..
NEW YORK: US-IndiaBioPharma & Healthcare Summit 2010 organized by the USA-India Chamber of Commerce in Boston recently attracted…..
NEW YORK: The USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce aimed at promoting and facilitating trade and investment between the United States and India, will organize its annual US-India….
BOSTON, Mass. — The recent U.S.-India BioPharma & Healthcare Summit 2010, organized by the USA-India Chamber of Commerce here, attracted over 350 senior biopharma executives, investors and academic leaders, becoming one of the leading biopharma events for senior R&D executives….
The USA-India Chamber of Commerce has said the Annual Budget presented by the Finance Minister Pranab Mukherjee is a massive piece of fiscal stimulus which would spur growth and employment…
Business Standard – View PDF
Deccan Herald – View PDF
The Hindu – View PDF
Hindustan Times – View PDF
News X – View PDF
The Times of India – View PDF
Zee TV – View PDF
BOSTON – India faces a lacuna in research and development funding, with lags in government investment and venture capital activity that are creating roadblocks to accelerating the country’s growth in pharmaceutical sector, experts said…
NEW YORK: Dr. Barry Bloom, a medical education pioneer in India, was presented with Distinguished Services Award by the USA-India Chamber of Commerce for his longstanding and deep commitment to help improve public health and biomedical science in India; his scientific contributions to immunology, leprosy and tuberculosis; and his passion for educating the next generation of Indian scientists and scholars…
Bostom, August 25 – The USA-India Chamber of Commerce has felicitated Dr Barry Bloom of Harvard…… Emphasising the need for a stronger interface between the industry, academia and NGO, Bloom said the US can learn a great deal from public private partnerships in India…
The USA-India Chamber of Commerce has felicitated Dr Barry Bloom of Harvard…… Felicitating Bloom, Rishi said he has four decades of selfless service to improve public health and medical education in India. Bloom’s involvement with India goes back to 1969 when he first visited India…
Boston, Aug 25 (PTI) The USA-India Chamber of Commerce has felicitated Dr Barry Bloom of Harvard…… the most impressive thing in India is its incredible creative range of public private partnerships. “Whether it is high quality high throughput model where paying patient on one side and poor patient on the other side get the best possible care at hospitals…
US-India BioPharma and Healthcare Summit, an annual summit organized by the USA-India Chamber of Commerce which brings together all stakeholders of the sector to facilitate trade and investments in US-India corridor, had attracted over 300 senior biotech, pharmaceuticals, medical devices and academic leaders this year……there is too much clinical data available in the world, but the challenge lies in converting that data into knowledge for drug discovery. India with its IT strengths can play a vital role….
…the necessity to leverage the global intellectual enterprise takes center stage…This is the time for Indian companies to ramp up their capacity and quality standards…
…As we see the pressure to reduce healthcare costs and find innovative solutions to unmet needs build up, the necessity to leverage the global intellectual enterprise takes centre stage….
…USA-India Chamber of Commerce applauded the efforts of Government of India’s initiative to make India an innovation hub by 2020 and termed it a bold initiative…
Notwithstanding the current global economic crisis, India’s pharmaceutical industry and its health care market are expected to grow rapidly in the next few years…
The Economic Times – View PDF
The Hindu – View PDF
Hindustan Times – View PDF
Mint – View PDF
Zeenews – View PDF
The Statesman – View PDF
India has the potential to emerge as a global innovation hub and the US’s collabortion with Indian pharma and health companies will not only help the two countries, but also entire world, eminent experts and industry leaders said…
…We have created an ecosystem where all stake holders meet to share and learn. This unique platform creates mutually beneficial opportunities for the US and Indian industry necessary to take the business to the next level,…
…There is an urgent need for US BioPharma industry to engage Indian academia and for Indian industry to connect with US academic institutions. Participants’ mood was very upbeat….
…Top tier life sciences focused venture capitalists, private equity firms and investment bankers have shown great interest in the Summit. Since the last Summit, some venture capitalists have set up India/Asia focused funds…
…The keynote address will be delivered on the theme ‘Policy Makers and Industry Leaders’ and Discussions will be held with Nobel Laureate Prof. Sydney Altman…
The meltdown of the US economy has raised legitimate concerns among the Indian establishment and industry. The US economy is in dire straits. The repercussions are being felt across a wide spectrum of industries, notably in financial, banking, housing, automobiles and retail-the leading growth engines in the past decade….
Over 350 execs and investors attend USAICC summit…
At USA-India Chamber of Commerce’s BioPharma Summit the minister spoke about collaborative initiatives between the two countries…
“Innovation and funding innovation will get a big boost from this Summit,” said Karun Rishi, President of the USA-India Chamber of Commerce. “Collaborative research and strategic alliances will be the key forces driving the business.”…
“The US-India BioPharma Summit is part of an ongoing dialogue with all the stakeholders including industry, investors, policy makers and academia,” said Karun Rishi, President of the USA-India Chamber of Commerce….
In his keynote address, Indian Minister of Science and Technology Kapil Sibal talked of an emerging intellectual property regime in India that would not only uphold the interests of indulging pharmaceutical companies but shall also match their investment on a 50:50 basis to build an environment to develop collaborative initiatives to mutual benefits in the field of agriculture, marine and health sciences…
…The result oriented work being done by the USA-India Chamber of Commerce to promote and facilitate biotechnology, pharmaceuticals and healthcare business and investments between the two countries is laudable.Globalization has favored the technology intensive industries in general and the biotech industry in particular…
Dr. Surinder Singh, Drug Controller General of India in his keynote address talked about implementation of an advanced “e governance drug regulatory system in India”. This electronic system, unique in itself is currently being developed with intense support from the Indian IT sector to suit the Indian context, following closer understanding of the functioning of its equivalent counterparts in the world- WHO, Health Canada and FDA.
